Sp
Spark (Roche)
Philadelphia PAFounded 2013400 employees
Private CapbiotechAcquiredOphthalmologyHematology
Platform: Luxturna RPE65
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| SPA-2229 | SPA-2229 | Phase 1 | 2 | KIF18A | CTCLRA | ||
| SPA-7602 | SPA-7602 | Preclinical | 1 | BCMA | PSP |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)